Literature DB >> 16841205

[Calcineurin inhibitors for topical therapy in psoriasis].

J Wohlrab1.   

Abstract

There are numerous possibilities for specific antiinflammatory therapy of psoriasis. One option is the use of calcineurin inhibitors. To date, only systemic administration of cyclosporine A is approved for this indication. Nonetheless cyclosporine A, tacrolimus and pimecrolimus can all be classed as effective anti-inflammatory agents for the therapy of psoriasis. Unfortunately, the vehicles currently available do not insure adequate topical delivery of these substances. Clinical efficacy of the preparations can be proven only when additional penetration-promoting measures are used or penetration-facilitating conditions exist. The entire group can be expected to play a greater role in the topical therapy of psoriasis if advances in vehicles and delivery systems are made.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16841205     DOI: 10.1007/s00105-006-1185-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  35 in total

1.  Pimecrolimus and tacrolimus for the treatment of intertriginous and facial psoriasis: are they effective?

Authors:  Michael Bigby
Journal:  Arch Dermatol       Date:  2005-09

2.  FK 506: a new therapeutic agent for severe recalcitrant psoriasis.

Authors:  K Abu-Elmagd; D Van Thiel; B V Jegasothy; C D Ackerman; S Todo; J J Fung; A W Thomson; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Topical tacrolimus in the treatment of inverse psoriasis in children.

Authors:  Jennifer A Steele; Christine Choi; Pearl C Kwong
Journal:  J Am Acad Dermatol       Date:  2005-10       Impact factor: 11.527

Review 4.  Pimecrolimus -- an anti-inflammatory drug targeting the skin.

Authors:  M Grassberger; M Steinhoff; D Schneider; T A Luger
Journal:  Exp Dermatol       Date:  2004-12       Impact factor: 3.960

5.  Tacrolimus ointment is effective for facial and intertriginous psoriasis.

Authors:  Mark Lebwohl; Amy Krupnick Freeman; M Shane Chapman; Steven R Feldman; Jennifer E Hartle; Alice Henning
Journal:  J Am Acad Dermatol       Date:  2004-11       Impact factor: 11.527

6.  Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.

Authors:  A B Gottlieb; C E M Griffiths; V C Ho; M Lahfa; U Mrowietz; D F Murrell; J-P Ortonne; G Todd; R Cherill; I Marks; S Emady-Azar; C F Paul
Journal:  Br J Dermatol       Date:  2005-06       Impact factor: 9.302

7.  Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream.

Authors:  B Amichai
Journal:  J Eur Acad Dermatol Venereol       Date:  2004-11       Impact factor: 6.166

8.  Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model.

Authors:  M Erdogan; J R Wright; V C McAlister
Journal:  Br J Dermatol       Date:  2002-06       Impact factor: 9.302

Review 9.  The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review.

Authors:  Noah Scheinfeld
Journal:  Dermatol Online J       Date:  2004-07-15

10.  Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study.

Authors:  I M Zonneveld; A Rubins; S Jablonska; A Dobozy; T Ruzicka; P Kind; L Dubertret; J D Bos
Journal:  Arch Dermatol       Date:  1998-09
View more
  1 in total

1.  Preparation and in vitro evaluation of tacrolimus-loaded ethosomes.

Authors:  Guiling Li; Chao Fan; Xinru Li; Yating Fan; Xiaoning Wang; Mei Li; Yan Liu
Journal:  ScientificWorldJournal       Date:  2012-05-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.